Mereo to present its osteogenesis imperfecta study data in Orlando

Mereo to present its osteogenesis imperfecta study data in Orlando

September 5, 2019 Off By Dino Mustafić

Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.

Mereo noted ithas reported in May 2019, positive early 6-month data from the open label arm of the study. The company said it expects to report 12-month data on all patients enrolled in the ASTEROID study in Q4 2019.

Mereo said that the patients in the trial had not been treated with bisphosphonates in the previous 3 months or other anabolic or anti-resorptive medications in the previous 6 months.